心脈醫療(688016.SH):取得外周高壓球囊擴張導管產品的醫療器械註冊證
格隆匯11月15日丨心脈醫療(688016.SH)公佈,近日,公司獲得國家藥品監督管理局頒發的關於外周高壓球囊擴張導管產品的醫療器械註冊證。
該產品適用於外周血管系統(包括髂動脈、股動脈、膕動脈、脛動脈、腓動脈、鎖骨下動脈和腎動脈)的經皮腔內血管成形術(PTA),並適用於治療自體或人造透析用動靜脈瘻的堵塞病變。同時適用於外周血管系統中的球囊擴張支架或自擴張支架的後擴張。
上述產品醫療器械註冊證的獲得,進一步豐富了公司現有產品種類,擴充公司在外周領域的產品線佈局,將進一步推動公司在外周領域的市場拓展,不斷滿足市場需求,從而進一步增強公司的核心競爭力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.